MedPath

Varlitinib

Generic Name
Varlitinib
Drug Type
Small Molecule
Chemical Formula
C22H19ClN6O2S
CAS Number
845272-21-1
Unique Ingredient Identifier
846Y8197W1

Overview

Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.

Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions

No associated conditions information available.

Research Report

Published: Oct 4, 2025

A Comprehensive Monograph on Fenfluramine (DB00574)

Executive Summary

Fenfluramine represents a molecule of profound duality in modern pharmacology, embodying a paradoxical journey from a widely proscribed anorectic agent to a highly valued anticonvulsant for rare and catastrophic pediatric epilepsies. Initially approved for obesity and later gaining notoriety as one half of the "Fen-Phen" combination, its widespread use was abruptly halted in 1997 due to an unacceptable risk of potentially fatal valvular heart disease (VHD) and pulmonary arterial hypertension (PAH). This cardiotoxicity was mechanistically linked to the activation of serotonin 5-HT2B receptors on cardiac valve fibroblasts. For over two decades, Fenfluramine was relegated to the annals of cautionary pharmaceutical tales.

However, a deeper understanding of its complex pharmacology has led to its remarkable resurrection. Fenfluramine exerts its effects through a multi-modal mechanism, acting not only as a potent serotonin releasing agent but also as a direct agonist at specific serotonin receptor subtypes (notably 5-HT1D and 5-HT2C) and as a positive modulator of the sigma-1 (σ1) receptor. This combination of enhanced inhibitory neurotransmission and dampened excitatory signaling provides a powerful, network-stabilizing effect. Recognizing this potential, researchers repurposed Fenfluramine at significantly lower doses for the treatment of intractable seizures.

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/09/10
Not Applicable
Terminated
National Cancer Centre, Singapore
2018/04/17
Phase 1
UNKNOWN
2017/12/11
Phase 1
Completed
2017/07/27
Phase 2
Completed
2017/04/26
Phase 2
Completed
2017/04/26
Phase 2
Withdrawn
2017/03/28
Phase 2
Completed
2017/03/17
Phase 1
Completed
2016/12/14
Phase 1
Terminated
2016/01/07
Phase 1
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.